At a glance
ClinicalIndex Comparison RecordN/ACompleted· 114 enrolled
Drug / intervention
Enterade +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blinded Phase 2 Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
In Brief
A clinical study evaluating Enterade, Placebo, and 1 other intervention for Multiple Myeloma and Non-Hodgkin's Lymphoma. Completed, enrolled 114 participants across 1 site.
Detailed Summary
This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant. The following interventions will be involved in this study: * Enterade plus standard supportive care * Placebo plus standard supportive care. The placebo will be a mixture of water, electrolytes, and sweetener.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Non-Hodgkin's Lymphoma
CountriesUnited States
CollaboratorsEntrinsic Health
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionMay 2019
Study CompletionJul 2020
TodayJul 2026
First PostedSep 29, 2016
Enrollment StartOct 1, 2016
Primary CompletionMay 1, 2019
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.8 years ago
Interventions
Enteradedietary
Placebodietary
Standard Supportive Careother